Clinical Trial Update: 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 5 mcg and 10 mcg tiotropium (Respimat) against placebo and ipratropium MDI in chronic obstructive pulmonary disease over 12 weeks. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Atrovent (ipratropium bromide)
• Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED